The Greenrose Holding Company Inc. (GNRS) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
GNRS steht fuer The Greenrose Holding Company Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Bewertet mit 43/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 15. März 2026The Greenrose Holding Company Inc. (GNRS) Gesundheitswesen & Pipeline-Uebersicht
Greenrose Holding Company Inc. cultivates, processes, and sells medical cannabis and derivative products. Operating within the specialty and generic drug manufacturing sector, the company focuses on production and distribution. With a high profit margin, Greenrose faces challenges typical of the evolving cannabis market, including regulatory hurdles and competition.
Investmentthese
Greenrose Holding Company Inc. presents a speculative investment opportunity within the cannabis sector. The company's high profit margin of 70.6% and gross margin of 59.1% suggest efficient operations, but the lack of market capitalization data and a negative beta of -170.34 indicate high volatility and potential risk. Growth catalysts include expanding product lines and entering new geographic markets as regulations evolve. However, investors should be aware of the risks associated with OTC-traded companies, including limited liquidity and disclosure. The company's success hinges on navigating regulatory hurdles and achieving sustainable growth in a competitive market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Profit Margin of 70.6% indicates strong profitability in its operations.
- Gross Margin of 59.1% reflects efficient cost management in production and sales.
- Beta of -170.34 suggests the stock price moves inversely to the market, indicating high volatility.
- The company operates in the rapidly evolving cannabis industry, presenting both opportunities and challenges.
- Headquartered in Amityville, New York, indicating a focus on the East Coast cannabis market.
Wettbewerber & Vergleichsunternehmen
Staerken
- High profit margin of 70.6%.
- Established cultivation and processing capabilities.
- Focus on medical cannabis market.
- Compliance with regulatory standards.
Schwaechen
- OTC listing indicates higher risk.
- Limited market capitalization data.
- Negative beta suggests high volatility.
- Dependence on evolving regulatory environment.
Katalysatoren
- Upcoming: Potential changes in federal cannabis regulations could create new market opportunities.
- Ongoing: Expansion into new geographic markets as legalization efforts progress.
- Ongoing: Development of new cannabis-based therapies through research and development.
- Ongoing: Strategic partnerships with healthcare providers to expand distribution channels.
- Ongoing: Increasing consumer acceptance of medical cannabis.
Risiken
- Potential: Increasing competition in the cannabis industry could erode market share.
- Potential: Changes in regulatory landscape could negatively impact operations.
- Potential: Fluctuations in cannabis prices could affect profitability.
- Ongoing: OTC listing indicates higher risk due to limited disclosure and oversight.
- Ongoing: Dependence on evolving regulatory environment creates uncertainty.
Wachstumschancen
- Expanding Product Lines: Greenrose can capitalize on the growing demand for diverse cannabis products by expanding its product lines to include edibles, concentrates, and topicals. The market for cannabis edibles alone is projected to reach $5 billion by 2028, presenting a significant revenue opportunity. Timeline: Within the next 2-3 years.
- Entering New Geographic Markets: As cannabis legalization expands across the United States and globally, Greenrose has the opportunity to enter new geographic markets. Targeting states with favorable regulatory environments and high population densities can drive significant revenue growth. Timeline: Ongoing, contingent on regulatory changes.
- Strategic Partnerships: Forming strategic partnerships with established healthcare providers and pharmaceutical companies can provide Greenrose with access to new distribution channels and customer bases. Collaborating on research and development can also lead to the creation of innovative cannabis-based therapies. Timeline: Within the next 1-2 years.
- Focus on Research and Development: Investing in research and development to identify new therapeutic applications for cannabis can differentiate Greenrose from its competitors and create a competitive advantage. Developing proprietary formulations and delivery methods can also enhance the company's intellectual property portfolio. Timeline: Ongoing.
- Acquisitions and Mergers: Pursuing strategic acquisitions and mergers can enable Greenrose to expand its market share, acquire new technologies, and diversify its product offerings. Targeting companies with complementary assets and capabilities can create synergies and drive long-term growth. Timeline: Opportunistic, based on market conditions.
Chancen
- Expansion into new geographic markets.
- Development of new cannabis-based therapies.
- Strategic partnerships with healthcare providers.
- Acquisition of complementary businesses.
Risiken
- Increasing competition in the cannabis industry.
- Changes in regulatory landscape.
- Potential for federal prohibition.
- Fluctuations in cannabis prices.
Wettbewerbsvorteile
- Proprietary cultivation techniques.
- Established distribution network.
- Brand recognition in specific markets.
- Compliance with regulatory standards.
Ueber GNRS
Founded in 2014 and headquartered in Amityville, New York, Greenrose Holding Company Inc. is a cannabis company involved in the production and sale of cannabis products. Through its subsidiaries, the company cultivates, processes, and packages medical cannabis and derivative products. Greenrose aims to serve the medical cannabis market by providing a range of products derived from cannabis. The company’s operations encompass the entire value chain from cultivation to packaging, ensuring quality control and product consistency. Greenrose’s strategy focuses on capturing a significant share of the market by leveraging its production capabilities and distribution network. The company operates in a highly regulated environment and must navigate complex legal frameworks at both state and federal levels. Greenrose is committed to adhering to the highest standards of compliance and safety in its operations. The company's current market position is influenced by the evolving legal landscape and increasing acceptance of medical cannabis.
Was das Unternehmen tut
- Cultivates medical cannabis.
- Processes raw cannabis into usable forms.
- Packages cannabis products for sale.
- Sells cannabis products to dispensaries and other retailers.
- Develops derivative cannabis products.
- Operates in compliance with state and local regulations.
Geschaeftsmodell
- Cultivation and processing of cannabis.
- Sales of cannabis products to dispensaries.
- Development and sale of derivative products.
- Revenue generation through product sales.
Branchenkontext
Greenrose Holding Company Inc. operates within the rapidly expanding cannabis industry, specifically in the specialty and generic drug manufacturing segment. The industry is characterized by evolving regulations, increasing acceptance of medical cannabis, and growing market demand. Companies like Greenrose face competition from both established players and new entrants. The market is driven by increasing legalization efforts and the growing recognition of cannabis's therapeutic benefits. The industry is also subject to significant regulatory scrutiny, impacting market access and operational costs.
Wichtige Kunden
- Medical cannabis dispensaries.
- Retail outlets selling cannabis products.
- Patients with medical cannabis prescriptions.
- Consumers in states with legal recreational cannabis.
Finanzdaten
Chart & Info
The Greenrose Holding Company Inc. (GNRS) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer GNRS verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer GNRS.
Kursziele
Wall-Street-Kurszielanalyse fuer GNRS.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von GNRS auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Nicole Conboy
CEO
Nicole Conboy serves as the CEO of Greenrose Holding Company Inc. Her background includes experience in managing teams and overseeing operations within the cannabis industry. She has a proven track record of driving growth and implementing strategic initiatives. Conboy is responsible for leading the company's overall strategy, managing its operations, and ensuring compliance with regulatory requirements. Her leadership is focused on expanding Greenrose's market presence and enhancing its product offerings. She is also committed to fostering a culture of innovation and collaboration within the company.
Erfolgsbilanz: Under Nicole Conboy's leadership, Greenrose has focused on streamlining its operations and expanding its product lines. Key achievements include improving production efficiency and enhancing the company's distribution network. Conboy has also played a crucial role in navigating the complex regulatory landscape and ensuring compliance with state and local laws. Her strategic decisions have contributed to the company's growth and profitability.
GNRS OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Greenrose Holding Company Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to companies on higher tiers or listed exchanges. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Lower regulatory oversight.
- Potential for price manipulation.
- Higher volatility.
- Liquidity constraints.
- Verify the company's financial statements.
- Research the company's management team.
- Assess the company's compliance with regulations.
- Evaluate the company's business model and competitive landscape.
- Review the company's risk factors.
- Check for any legal or regulatory issues.
- Consult with a financial advisor.
- Established cultivation and processing capabilities.
- Focus on the medical cannabis market.
- Compliance with regulatory standards.
- Experienced management team.
GNRS Healthcare Aktien-FAQ
What are the key factors to evaluate for GNRS?
The Greenrose Holding Company Inc. (GNRS) currently holds an AI score of 43/100, indicating low score. Key strength: High profit margin of 70.6%.. Primary risk to monitor: Potential: Increasing competition in the cannabis industry could erode market share.. This is not financial advice.
How frequently does GNRS data refresh on this page?
GNRS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven GNRS's recent stock price performance?
Recent price movement in The Greenrose Holding Company Inc. (GNRS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: High profit margin of 70.6%.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider GNRS overvalued or undervalued right now?
Determining whether The Greenrose Holding Company Inc. (GNRS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying GNRS?
Before investing in The Greenrose Holding Company Inc. (GNRS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GNRS to a portfolio?
Potential reasons to consider The Greenrose Holding Company Inc. (GNRS) depend on individual investment goals and risk tolerance. A key strength identified by analysis: High profit margin of 70.6%.. Additionally: Established cultivation and processing capabilities.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of GNRS?
Yes, most major brokerages offer fractional shares of The Greenrose Holding Company Inc. (GNRS) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track GNRS's earnings and financial reports?
The Greenrose Holding Company Inc. (GNRS) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for GNRS earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Limited information available due to OTC listing.
- AI analysis pending for GNRS.